Solutions
Emerging Biopharma Program
US Emerging Biopharma and Medical Device Sponsors
Jeeva launched an innovative program on Aug. 1, 2023, to support early phase innovation in the “US Emerging Biopharma and medical device industry,” struggling to cope with the short-term effects of the Inflation Reduction Act 2022.
Check our latest PR for Emerging Biopharma
The Inflation Reduction Act: How Price Controls Could Disrupt Clinical Trials and Stifle Medical Innovation The Inflation Reduction Act of 2022 has introduced drug pricing controls that may initially benefit patients. However, these controls could have unintended consequences on drug development and investment eventually. To mitigate these pressures, there is an opportunity to modernize clinical trials. Dr. Harsha Rajasimha, CEO of Jeeva Trials, plans to help biopharmaceutical and medical device sponsors reduce the costs of early phase clinical trials and overcome these challenges.
Compliance Programs Supported
Testimonials
